文献速递淋巴瘤

马拉维弥漫性大B细胞淋巴瘤的成熟结局与预后指数:一项前瞻性队列研究

Mature outcomes and prognostic indices in diffuse large B-cell lymphoma in Malawi: a prospective cohort.
PubMed 文献 · Br J Haematol · 2018-11-18

该研究在马拉维2013-2017年纳入86例≥18岁弥漫性大B细胞淋巴瘤(DLBCL)患者,接受CHOP化疗及HIV阳性者同步抗逆转录病毒治疗(ART)。2年总生存率为38%(95%CI 28-49),HIV状态与死亡率无关,ECOG体能状态≥2和LDH>2倍正常上限与死亡率相关。简化的预后模型(LDH>2×ULN且PS≥2)至少与年龄调整的国际预后指数表现相当,但需验证。

要点

  • 马拉维DLBCL前瞻性队列2年总生存率为38%(95%CI 28-49)。
  • ECOG体能状态≥2和LDH>2倍正常上限与死亡率相关,HIV状态与死亡率无关。
  • 简化预后模型(LDH>2×ULN且PS≥2)至少与年龄调整的国际预后指数表现相当,但需验证。

核心结论

  • DLBCL在撒哈拉以南非洲可成功治疗,且结局不因HIV状态而异。
  • 简化的预后模型预后良好,在资源有限环境中可能更易使用,但需验证。

研究设计与样本

  • 前瞻性队列研究,2013-2017年在马拉维纳入86例年龄≥18岁的DLBCL患者,接受CHOP化疗,HIV阳性者同步接受抗逆转录病毒治疗(ART)。

主要发现

  • 86例参与者平均年龄47岁(标准差13),54例(63%)为男性,51例(59%)HIV阳性,其中34例(67%)在DLBCL诊断时已接受ART。
  • 中位CD4计数为0.113 cells×10^9/l(四分位距[IQR] 0.062-0.227),25例(49%)HIV病毒载量<400 copies/μl。
  • 参与者接受中位6个周期CHOP(IQR 4-6),无患者失访,2年总生存率为38%(95%CI 28-49)。
  • 多变量分析中,ECOG体能状态(PS)≥2和乳酸脱氢酶(LDH)>2倍正常上限(ULN)与死亡率相关;HIV状态与死亡率无关。
  • LDH>2×ULN和PS≥2的简化预后模型表现至少与年龄调整的国际预后指数相当。

关键数值与推荐

  • 简化预后模型纳入LDH>2×ULN和PS≥2,其预后表现至少与年龄调整的国际预后指数相当。

临床怎么用

  • DLBCL在撒哈拉以南非洲可成功治疗,且结局不因HIV状态而异。
  • 简化的预后模型在资源有限环境中可能更易使用,但需验证。

局限性

  • 简化的预后模型需验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outcomes for diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa (SSA) are poorly described. We report mature data from one of the first prospective SSA cohorts. Patients aged ≥18 years with DLBCL were enrolled in Malawi 2013-2017. Participants were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy and concurrent antiretroviral therapy (ART) if positive for human immunodeficiency virus (HIV+). Eighty-six participants (mean age 47 years, standard deviation 13) were enrolled: 54 (63%) were male and 51 (59%) were HIV+, of whom 34 (67%) were on ART at DLBCL diagnosis. Median CD4 count was 0·113 cells × 109 /l (interquartile range [IQR] 0·062-0·227) and 25 (49%) had HIV viral load <400 copies/μl. Participants received median six cycles CHOP (IQR 4-6). No patients were lost to follow-up and the 2-year overall survival was 38% (95% confidence interval 28-49). In multivariable analyses, Eastern Cooperative Oncology Group performance status (PS) ≥2 and lactate dehydrogenase (LDH) >2× upper limit of normal (ULN) were associated with mortality. HIV status was not associated with mortality. A simplified prognostic model of LDH >2× ULN and PS ≥2 performed at least as well as the age-adjusted International Prognostic Index. DLBCL can be successfully treated in SSA and outcomes did not differ by HIV status. A simplified prognostic model prognosticates well and may be easier to use in resource-limited settings but requires validation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Painschab MS, Kasonkanji E, Zuze T, et al. Mature outcomes and prognostic indices in diffuse large B-cell lymphoma in Malawi: a prospective cohort. Br J Haematol. 2018. PMID: 30450671. doi:10.1111/bjh.15625

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。